Analysts await Horizon Pharma plc (NASDAQ:HZNP) to report earnings on May, 09 for the fiscal quarter ending Mar 2016.

They expect $0.38 EPS, up 57.89% or $0.22 from last year’s $0.16 per share.

At the moment 11 analysts are watching Horizon Pharma plc (NASDAQ:HZNP), 5 rate it “Buy”, 4 “Outperform”, 1 “Underperform”, 1 “Sell”, while 0 “Hold”.

Looking forward, for the quarter ending Jun-16, 9 analysts have a mean sales target of 231.20 million. For the quarter ending Sep-16, 9 analysts have a mean sales target of 271.20 million whilst for the year ending Dec-16, 10 analysts have a mean target of 1,001.33 million.

In terms of earnings per share, 11 analysts have a 0.49 EPS mean target for the quarter ending Jun-16, for the quarter ending Sep-16, 11 analysts have a 0.70 EPS mean target and for the quarter ending Sep-16 there are 11 estimates of 2.30 EPS.

The biggest institutional shareholders in Horizon Pharma plc include Fidelity Management and Research Company which owns 18 million shares in the company valued at $494.64 million. Lone Pine Capital LLC is the second biggest holder with 16 million shares currently valued at 338.07 million whilst Deerfield Management Co has 12 million shares valued at 253.21 million.

Total shares held by institutions as of the most recent company filings are 135,278,514 with a reported 21,460,881 bought and 10,828,858 sold. These holdings make up 84.5% of the company’s outstanding shares.

Currently insiders hold 498,776 shares in the business which makes up 0.31% of shares. The biggest holder currently is Mr. Timothy P. Walbert who owns 324,493 shares (0.20% of those outstanding), whilst Dr Virinder Nohria holds 214,836 (0.13% of shares outstanding) and Jeffrey W. Sherman,M.D. holds 160,100 (0.10% of shares outstanding).

The stock decreased 8.09% or $1.18 during the last trading session, hitting $16.88. Horizon Pharma plc (NASDAQ:HZNP) has fallen 32.05% over the past 6 months and is downtrending.